Big Brothers Big Sisters of Tampa Bay’s Post

For more than 80 years, the values of diversity, equity and inclusion have been part of our Credo and culture at Johnson & Johnson and woven into how we do business every day. In our We All Belong: 2023 DEI Impact Review, we have shared the sustained and tangible ways in which our DEI actions continue to strengthen our business to meet the needs of patients, providers and communities around the world. Here's a glimpse of what you’ll find in the Review: ➡️ Advancing Diversity in Clinical Trials: We’ve doubled clinical trial participation by patients of color compared to last year. ➡️ Investing in Early-stage Innovators: JLABS, our global life science startup incubator, awarded $11.9 million in 2023 to healthcare innovators from underrepresented backgrounds. ➡️ Empowering Communities: We’ve invested $80 million in programs to close the racial health gap in the U.S. ➡️ Fostering a Culture of Belonging: 85% of employees agree that Johnson & Johnson provides an inclusive work environment. Learn how Johnson & Johnson is continuing to advance the power of DEI to create a healthier, more equitable world at belong.jnj.com.

On my first day of orientation for Biogen, I knew this was no ordinary place. From the passion of the employees to the thoughtful crafting of the onboarding process, it's been such an enlightening and inspiring few months. But what really sat with me was the actual patient who spoke with us live, to close out our orientation day. She was a proud Puerto Rican woman who shared her story and deep appreciation for the work we do every day--especially our focus on expanding access to our therapeutics and health equity. Her words struck a chord deep in my soul and left me with a new employee experience I will honestly never forget.    I'm proud to be a part of a leading biotech company that sees #healthequity and expanding access to life-saving medications as not only an essential pillar of corporate responsibility, but also an intrinsic part of who we are.   Last year, Biogen made tremendous progress on this: from expanding our presence to 70+ countries, to driving a 35% increase in patients with access to our treatments through our Early Access Program. I'm equally inspired by our ongoing commitment to diversifying #clinicaltrials, with specific race and ethnicity enrollment targets that we're laser focused on achieving.   The more I learn about Biogen, the prouder I am to be here--and to be positioned to make transformational impact on drug development, through the power of health equity. 💙 Check out the highlights of our impact in our 2023 Corporate Responsibility Report: https://lnkd.in/eqKRYUTR    #ESGreport #TeamBiogen #CaringDeeply #Healthcareonlinkedin

Corporate changemakers are grappling with how to transform their social impact commitments into action, and many are encountering interference within their companies that can slow down progress and reduce impact. Join FSG and leaders from AARP, Bristol Myers-Squibb, Merck, and Sanofi for an interactive discussion on Oct 1 from 12-1PM ET on how to navigate this moment. Register here: https://lnkd.in/et4F23dy

Today's a fresh start to SIZE UP your skills, knowledge, and network! What opportunities will you seize this week? Helix Biogen Institute Dr. Oladipo Elijah Kolawole (Ph.D) #MondayInspiration #GrowthMindset #MotivationMonday #NewWeekNewGoals #SuccessTips

A Global Approach to DEI in Clinical Trials Robina Weermeijer Boehringer Ingelheim As the world is becoming more and more diverse there is a big need to consider a wide audience when conducting clinical trials. In this presentation, you'll get insights into why it's important to look at diversity, equity, and inclusion on a global level and which efforts are being made by Boehringer Ingelheim in this space through collaboration with diverse stakeholders. https://bit.ly/3jRNCin #ScopeSummit #ClinicalTrials

In partnership with Eli Lilly and Company, NEHI is pleased to release its final report on a two-year community focused effort to improve clinical trial diversity in Indiana. The project demonstrated the importance of improving knowledge and awareness about clinical trials by involving trusted messengers. With input and direction from a board of researchers, community-based organizations, and other health industry stakeholders, NEHI and Lilly led an initiative that relied on faith-based leaders with deep connections to the Black community to share information about the research process and the role of clinical research trials. Please read our full report to learn more about the impact of the initiative and the lessons we learned. We hope that these can inform similar community-focused efforts. Thank you to Kristi Mitchell, who partnered with NEHI throughout the work. https://lnkd.in/eeCZAzPg #HealthEquity #ClinicalTrials

One thing I’ve learned over the years from working in large pharma to leading startups is that real success comes from collaboration. When R&D, clinical, and commercial teams are truly aligned, we can bring the best out of our people, our products and make a real difference for patients. I will be sharing more about this today at Fierce Life Sciences Events New Product Planning Summit on a panel discussing: “Successful Collaboration Strategies Across R&D, Clinical, and Commercial Teams.” Throughout my career, I’ve seen how breaking down silos and building strong cross-functional relationships can lead to faster, more innovative product development. It’s all about creating a culture where collaboration isn’t just a goal—it’s a daily practice. I’ll be joined by some fantastic panelists: Erica Paine, VP of Value & Market Access, Chiesi, Susan Nemetz, Founder & CEO of Corval, Cathi Ahearn, SVP of Worldwide Commercial Portfolio Strategy at Bristol Myers Squibb, and Josh Meidenbauer, Senior Director of New Product Planning at Intellia Therapeutics. We’ll dive into how to improve communication between teams, share real-world examples of what’s worked, and discuss why getting everyone on the same page early on is key to moving assets forward smoothly. If you’re at the summit, I’d love to catch up and exchange ideas on how we can keep pushing forward through strong collaboration. Hope to see you there! #fiercelifesciences #newproductplanningsummit https://lnkd.in/ejZSiAqs

At AstraZeneca, we stand behind scientists who are dedicated to finding cures for the world's most lethal diseases. This commitment means that continuous learning is an integral part of our culture. Here, learning and adaptability are not just concepts; they are our way of life. What is the culture of learning at your organization?

One week till the Black Pharma ‘Together We Can’ annual summit. This year's theme, ‘Breaking the Glass Ceiling’ will explore the challenges and triumphs faced by under-represented professionals in the pharmaceutical industry and provide practical strategies for career advancement. Summit Highlights: • Networking and Exhibition at various points throughout the night. Network with potential mentors, and future employers. Discover exciting career opportunities from industry giants who share our passion for diversity and inclusion who will be at the event to connect with attendees including our generous sponsors. • Early Careers Q&A: Get answers to your burning questions about starting and advancing your career in pharma from experienced professionals. • Panel Discussion and Q&A : Join a thought-provoking panel discussion featuring industry leaders who will share their insights on overcoming challenges, breaking down barriers, and achieving success. • keynote speech by Dr. Marcia Philbin, Chief Executive of the Faculty of Pharmaceutical Medicine. Gain valuable takeaways and inspiration from our final speaker as we wrap up the summit. Join us at the Black Pharma Annual Summit to be part of something truly impactful. Register now to secure your spot! Registration closes 11 a.m this Friday. https://ow.ly/gkHx50TvgsP #BlackPharma #DiversityAndInclusion #LeadershipDevelopment #PharmaceuticalIndustry

🎯 Medicines Discovery Catapult strengthens its Senior Leadership Team with two Executive appointments: Chief Commercial Officer and its first Managing Director. ▶️ Dr Francesca Sadler has joined MDC as Chief Commercial Officer, bringing over 20 years’ experience in commercialising high-quality scientific services to both UK and international communities. ▶️ In addition, we have appointed our first Managing Director, Dr Mike Strange, who will join the organisation in February. Mike brings strong, complementary life sciences leadership skills to MDC. At GSK, he established several industry-leading collaborations, including the Tres Cantos Open Lab and the Africa Non-Communicable Diseases Open Lab. As Head of Global Health at LifeArc, he worked closely with MDC to design and launch the world-leading PACE collaborative R&D programme. 💬 Professor Chris Molloy, CEO of Medicines Discovery Catapult, said: “I warmly welcome Francesca and Mike to MDC, bolstering our Executive team with their deep-rooted expertise and an ambition for helping our sector. We look forward to working together at the frontier of drug R&D and to making every move count for our nation’s entrepreneurial scientists.” Read more: https://hubs.li/Q032dzm50 #DrugDiscovery